Ashvattha Therapeutics is a Phase 2 clinical stage company with a lead program treating hyperinflammation. The Company has a pipeline of drugs to treat ophthalmology, oncology, and inflammatory diseases. We are seeking partners and investors to advance our programs.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
OP-101 through wholly owned subsidiary, Orpheris
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):